BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29671222)

  • 1. Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer.
    Zenzola V; Cabezas-Quintario MA; Arguelles M; Pérez-Fernández E; Izarzugaza Y; Correa A; García-Foncillas J
    Clin Transl Oncol; 2018 Nov; 20(11):1448-1454. PubMed ID: 29671222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas.
    Mrklić I; Ćapkun V; Pogorelić Z; Tomić S
    Pathol Res Pract; 2013 May; 209(5):296-301. PubMed ID: 23601837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.
    Hao S; He ZX; Yu KD; Yang WT; Shao ZM
    Oncotarget; 2016 Apr; 7(17):24824-31. PubMed ID: 27050075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Wang Y; Ji L; Wu J; Di G; Liu G; Yu K; Shao Z; Wang Z
    Sci Rep; 2020 Jan; 10(1):225. PubMed ID: 31937819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
    Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
    Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study.
    Tashima R; Nishimura R; Osako T; Nishiyama Y; Okumura Y; Nakano M; Fujisue M; Toyozumi Y; Arima N
    PLoS One; 2015; 10(7):e0119565. PubMed ID: 26177501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
    Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
    PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
    Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
    Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients.
    Gui Y; Xu S; Yang X; Gu L; Zhang Z; Luo X; Chen L
    Biomark Med; 2016 Jul; 10(7):771-90. PubMed ID: 27339713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
    Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
    PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.
    Wang RX; Chen S; Jin X; Shao ZM
    Sci Rep; 2016 Jul; 6():30091. PubMed ID: 27426056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
    Zhukova LG
    Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.